0001558370-21-015515.txt : 20211110 0001558370-21-015515.hdr.sgml : 20211110 20211110163043 ACCESSION NUMBER: 0001558370-21-015515 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 14 CONFORMED PERIOD OF REPORT: 20211110 ITEM INFORMATION: Results of Operations and Financial Condition ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20211110 DATE AS OF CHANGE: 20211110 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Sigilon Therapeutics, Inc. CENTRAL INDEX KEY: 0001821323 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 474005543 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-39746 FILM NUMBER: 211397140 BUSINESS ADDRESS: STREET 1: 100 BINNEY STREET STREET 2: STE 600 CITY: CAMBRIDGE STATE: MA ZIP: 02142 BUSINESS PHONE: 617-336-7540 MAIL ADDRESS: STREET 1: 100 BINNEY STREET STREET 2: STE 600 CITY: CAMBRIDGE STATE: MA ZIP: 02142 8-K 1 sgtx-20211110x8k.htm 8-K
0001821323false00018213232021-11-102021-11-10

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): November 10, 2021

SIGILON THERAPEUTICS, INC.

(Exact name of registrant as specified in its charter)

Delaware

001-39746

47-4005543

(State or other jurisdiction

(Commission

(IRS Employer

of incorporation)

File Number)

Identification No.)

100 Binney Street, Suite 600, Cambridge, MA

02142

(Address of principal executive offices)

(Zip Code)

(Registrant’s telephone number, including area code): (617) 336-7540

Not Applicable

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Trading

Name of each exchange

Title of each class

    

Symbol(s)

    

on which registered

Common Stock, $0.001 par value per share

SGTX

The Nasdaq Global Select Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

Item 2.02 Results of Operations and Financial Condition.

On November 10, 2021, Sigilon Therapeutics, Inc. (the “Company”) issued a press release announcing the Company’s financial results for the quarter ended September 30, 2021. A copy of this press release is furnished as Exhibit 99.1 and is incorporated herein by reference.

The information in this Form 8 K (including Exhibit 99.1 attached hereto) is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference into any filing by the Company, under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filling.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits

Exhibit

No.

Description

99.1

Press Release Issued by Sigilon Therapeutics, Inc. on November 10, 2021

104

Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

SIGILON THERAPEUTICS, INC.

By:

/s/ Rogerio Vivaldi Coelho, M.D.

Rogerio Vivaldi Coelho, M.D.

President and Chief Executive Officer

Date: November 10, 2021

EX-99.1 2 sgtx-20211110xex99d1.htm EX-99.1

Exhibit 99.1

Graphic

Sigilon Therapeutics Reports Third Quarter 2021 Financial Results and Business Highlights

Company expects to complete its investigation of the clinical hold on its Phase 1/2 trial of SIG-001
in hemophilia A by year-end

On track to initiate a Phase 1/2 trial of SIG-005 for MPS-1 in the fourth quarter of 2021

Company appoints May Orfali, M.D., M.B.A, as Chief Medical Officer

Cambridge, MA—November 10, 2021—Sigilon Therapeutics, Inc. (NASDAQ: SGTX), a biotechnology company that seeks to develop functional cures for chronic diseases through its Shielded Living Therapeutics™ platform, today reported financial results for the third quarter ended September 30, 2021 as well as certain other business highlights.

“In the third quarter, we made meaningful progress advancing the development of our lysosomal disease program, while strengthening our leadership team to bolster our clinical and R&D capabilities,” said Rogerio Vivaldi, M.D., President and CEO of Sigilon. “Most recently, we welcomed Dr. May Orfali as Chief Medical Officer. We believe May’s insights will have an immediate impact on our Company’s operations and overall development strategy.”

Continued Dr. Vivaldi: “We remain committed to working with regulators to resolve the clinical hold on our Phase 1/2 trial of SIG-001 in hemophilia A and we anticipate completing our thorough investigation by year-end. In parallel, we have made meaningful progress advancing the development of our lysosomal disease program. Of note, our CTA for SIG-005 in MPS-1 was accepted in the UK and we received our second orphan drug designation for this product candidate, underscoring the global need for new treatment options to manage patients with this rare lysosomal disease. Each of these milestones represents an important step in advancing the development of SIG-005.

Recent Program Highlights

In July 2021, the Phase 1/2 study of SIG-001 in hemophilia A was placed on clinical hold by the U.S. Food and Drug Administration (FDA). To date, three patients have been dosed with SIG-001 and are continuing to be monitored by study protocol. The clinical hold was initiated following Sigilon’s submission of a serious adverse event (SAE) and temporary enrollment halt to the FDA and other regulatory agencies relating to the development of inhibitors to FVIII in the third patient. The Company expects to complete its investigation of this event before year-end.

In September 2021, the Medicines and Healthcare Products Regulatory Agency (MHRA) in the United Kingdom accepted the Company’s Clinical Trial Application (CTA) for SIG-005 in mucopolysaccharidosis type I (MPS-1). In addition, the Company filed a CTA in Brazil for SIG-005 in July 2021 and plans to submit an Investigational New Drug Application to the FDA.


In October 2021, the European Commission granted orphan drug designation to SIG-005 for the treatment of MPS-1.

Sigilon presented results from several ongoing preclinical studies in the rare lysosomal diseases MPS-1, MPS-2 and MPS-6 at the 16th International Symposium on MPS and Related Diseases (MPS 2021), which took place July 23 – 25, 2021.

Corporate Updates

May Orfali, M.D., M.B.A., will join the Company as an EVP and Chief Medical Officer (CMO), effective as of November 29, 2021, to lead the Company’s clinical development and medical affairs functions. Dr. Orfali has over 25 years of drug development experience across all phases of clinical development. Prior to joining Sigilon, Dr. Orfali held a number of executive leadership roles, most recently as president of Rare Disease & Oncology Consulting, LLC where she served as interim CMO for multiple small biotech companies in the rare disease and oncology space. Prior to that, she was the CMO of CANbridge Life Sciences, where she led the clinical development and medical affairs group, and Executive Director, Global Product Development at Pfizer, where she was responsible for patient-focused drug development across multiple rare disease assets including hemophilia.

Susan Drapeau, Ph.D., was promoted from SVP, Head of Pre-clinical Development to EVP, Chief Pre-clinical Operations Officer. Dr. Drapeau has over 20 years of industry experience in cell therapy, biologics, biomaterials, protein therapies and medical device development.

In July, Ajay Rai, M.B.A., joined the Company as SVP, Head of Business Development. Mr. Rai brings over two decades of business development, finance and partnering experience in the life sciences industry to Sigilon.

Sigilon has initiated a search for a full-time Chief Financial Officer (CFO). In the meantime, the Company has entered into a consulting agreement with Michael Wyzga, M.B.A. Previously, Mr. Wyzga served in various senior management positions, including CFO at Genzyme Corporation for over a decade.

Anticipated Milestones

Sigilon expects to initiate a Phase 1/2 trial of SIG-005 for MPS-1 in the fourth quarter of 2021.

The Company expects to provide up to 12 months of follow-up data for three patients from the Phase 1/2 safety and dose-ranging study of SIG-001 in severe to moderate-severe hemophilia A in the fourth quarter of 2021.

Financial Results

Cash Position: Cash was $140.4 million as of September 30, 2021 compared to $202.2 as of December 31, 2020.

R&D Expenses: Research and development expenses were $16.6 million for the third quarter of 2021 compared to $13.4 million for the third quarter of 2020. The increase in research and development expenses was primarily related to ongoing platform, pipeline, and development

activities related to Sigilon’s SIG-005 and SIG-007 programs, which received orphan drug designation in December 2020 and March 2021, respectively. During the third quarter of 2021, expenses increased for SIG-005 as the Company’s CTA was accepted by MHRA in the United Kingdom and the Company filed a CTA in Brazil. The Company expects to initiate a Phase 1/2 trial of SIG-005 for MPS-1 in the fourth quarter of 2021. Personnel expenses increased primarily as a result of the increase in headcount in Sigilon’s research and development function and increases in stock-based compensation. These increases were partially offset by a reduction of $2.9 million associated with Sigilon’s SIG-002 program. The decrease in SIG-002 related expenses was due to timing of preclinical activities.

G&A Expenses: General and administrative expenses were $5.0 million for the third quarter of 2021 compared to $3.3 million for the third quarter of 2020. The increase in general and administrative expenses was driven by a $1.2 million increase in personnel expenses, which was primarily the result of an increase in headcount and an increase in stock-based compensation. Stock-based compensation expense increased to $1.2 million from $0.4 million for the three months ended September 30, 2020. In addition, the increase in general and administrative expenses was driven by a $0.8 million in the expansion of personnel and internal infrastructure to support our operations as a public company.

Net Loss: Net loss was $20.2 million for the third quarter ended September 30, 2021 compared to $13.2 million for the same period of 2020.

About Sigilon Therapeutics

Sigilon Therapeutics seeks to develop functional cures for chronic diseases through its Shielded Living Therapeutics™ platform. Sigilon’s product candidates are non-viral engineered cell-based therapies designed to produce the crucial proteins, enzymes or factors needed by patients living with chronic diseases such as hemophilia, lysosomal diseases and diabetes. The engineered cells are protected by Sigilon’s Afibromer™ biomaterials matrix, which shields them from immune rejection and fibrosis. Sigilon was founded by Flagship Pioneering in conjunction with Daniel Anderson, Ph.D., and Robert Langer, Sc.D., of the Massachusetts Institute of Technology.

Forward-Looking Statements

This press release includes forward-looking statements. These forward-looking statements generally can be identified by the use of words such as “anticipate,” “expect,” “plan,” “could,” “may,” “will,” “believe,” “estimate,” “forecast,” “goal,” “project,” and other words of similar meaning. These forward-looking statements address various matters, including the timing for the initiation of our Phase 1/2 clinical trial of SIG-005 in MPS-1, the impact and timing of our CMO hiring, the timing of our investigation of the clinical hold of our Phase 1/2 clinical study of SIG-001 in Hemophilia A including the timing of our meeting with the FDA and other regulatory agencies and anticipated follow-up data for three patients from our Phase 1/2 clinical study of SIG-001. Each forward-looking statement contained in this press release is subject to risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statement. Applicable risks and uncertainties include, among others, that favorable preclinical results are not predictive of clinical trial results, our ability to resolve the clinical hold on SIG-001, the FDA or other regulators may request additional preclinical studies or clinical trials beyond those that we currently anticipate, manufacturing changes may not have the desired effect, and the risks identified under the heading “Risk Factors” in our Quarterly Report on Form 10-Q for the quarterly period ended September 30, 2021, and filed with the Securities and Exchange Commission (the “SEC”), as well as the other information we file with the SEC. We caution investors not to place considerable reliance on the forward-looking statements contained in


this press release. You are encouraged to read our filings with the SEC, available at www.sec.gov, for a discussion of these and other risks and uncertainties. The forward-looking statements in this press release speak only as of the date of this document, and we undertake no obligation to update or revise any of these statements. Our business is subject to substantial risks and uncertainties, including those referenced above. Investors, potential investors, and others should give careful consideration to these risks and uncertainties.

Sigilon Therapeutics, Inc.

Condensed Consolidated Balance Sheets

(in thousands, except share and per share amounts)

(Unaudited)

September 30, 

December 31, 

    

2021

   

2020

Assets

 

  

 

  

Current assets:

 

  

 

  

Cash

$

140,393

$

202,229

Accounts receivable (inclusive of $27 and $63 from a related party at September 30, 2021 and December 31, 2020, respectively)

 

27

 

177

Prepaid expenses and other current assets

 

3,531

 

1,729

Restricted cash—current

 

75

 

75

Total current assets

 

144,026

 

204,210

Property and equipment, net

 

3,910

 

2,991

Right-of-use assets

 

14,568

 

16,731

Restricted cash

 

1,293

 

1,118

Total assets

$

163,797

$

225,050

Liabilities, convertible preferred stock and stockholders’ equity (deficit)

 

  

 

  

Current liabilities:

 

  

 

  

Accounts payable

$

3,226

$

1,988

Accrued expenses and other current liabilities

 

7,657

 

7,892

Lease liabilities, current portion

 

5,673

 

5,361

Deferred revenue from related party, current portion

 

24,310

 

31,777

Total current liabilities

 

40,866

 

47,018

Lease liability, net of current portion

 

9,442

 

11,893

Long-term debt, net of discount

 

20,009

 

19,807

Other liabilities

 

176

 

176

Total liabilities

$

70,493

$

78,894

Stockholders’ equity

 

  

 

  

Common stock, par value $0.001 per share; 175,000,000 shares authorized at September 30, 2021 and December 31, 2020; 32,201,338 and 31,464,989 shares issued and outstanding at September 30, 2021 and December 31, 2020, respectively

 

32

 

31

Preferred stock, par value $0.001 per share; 25,000,000 shares authorized at September 30, 2021 and December 31, 2020; no shares issued and outstanding at September 30, 2021 and December 31, 2020

 

 

Additional paid-in capital

 

288,766

 

282,053

Accumulated deficit

 

(195,494)

 

(135,928)

Total stockholders’ equity

 

93,304

 

146,156

Total liabilities, convertible preferred stock and stockholders’ equity

$

163,797

$

225,050


Sigilon Therapeutics, Inc.

Condensed Consolidated Statements of Operations and Comprehensive Loss

(Unaudited, in thousands, except per share data)

Three Months Ended September 30, 

Nine Months Ended September 30, 

    

2021

    

2020

    

2021

    

2020

Revenue

 

  

 

  

 

  

 

  

Collaboration revenue

$

1,947

$

4,201

$

7,609

$

9,618

Operating expenses:

 

 

 

 

Research and development

 

16,645

 

13,425

 

50,381

39,151

General and administrative

5,041

3,334

15,572

9,023

Total operating expenses

 

21,686

 

16,759

 

65,953

 

48,174

Loss from operations

 

(19,739)

 

(12,558)

 

(58,344)

 

(38,556)

Other income (expense), net:

 

  

 

  

 

  

 

  

Interest income

 

56

30

 

212

268

Interest expense

 

(499)

(293)

 

(1,481)

(697)

Other income (expense)

 

26

(20)

 

47

(47)

Change in fair value of preferred stock warrant liability

 

(10)

 

(44)

Loss on extinguishment of debt

 

(343)

 

(343)

Total other expense, net

 

(417)

 

(636)

 

(1,222)

 

(863)

Net loss and comprehensive loss

$

(20,156)

$

(13,194)

$

(59,566)

$

(39,419)

Net loss per share attributable to common stockholders—basic and diluted

$

(0.63)

$

(2.47)

$

(1.88)

$

(7.56)

Weighted average common stock outstanding—basic and diluted

 

32,055,551

 

5,338,177

 

31,707,068

 

5,214,818

SOURCE: Sigilon Therapeutics, Inc.

Investor Contact
Robert Windsor, Jr., J.D.

VP, Head of Investor Relations

Sigilon Therapeutics
robert.windsor@sigilon.com
617-586-3837

Media Contacts
Amy Bonanno
Solebury Trout
abonanno@soleburytrout.com
914-450-0349

Brandon Hagen

Manager, Communications

Sigilon Therapeutics

brandon.hagen@sigilon.com

617-586-2851

##


GRAPHIC 3 sgtx-20211110xex99d1001.jpg GRAPHIC begin 644 sgtx-20211110xex99d1001.jpg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sgtx-20211110.xsd EX-101.SCH 00090 - Document - Document and Entity Information link:presentationLink link:calculationLink link:definitionLink EX-101.LAB 5 sgtx-20211110_lab.xml EX-101.LAB EX-101.PRE 6 sgtx-20211110_pre.xml EX-101.PRE XML 7 sgtx-20211110x8k_htm.xml IDEA: XBRL DOCUMENT 0001821323 2021-11-10 2021-11-10 0001821323 false 8-K 2021-11-10 SIGILON THERAPEUTICS, INC. DE 001-39746 47-4005543 100 Binney Street Suite 600 Cambridge MA 02142 617 336-7540 false false false false Common Stock, $0.001 par value per share SGTX NASDAQ true false XML 8 R1.htm IDEA: XBRL DOCUMENT v3.21.2
Document and Entity Information
Nov. 10, 2021
Document and Entity Information [Abstract]  
Document Type 8-K
Document Period End Date Nov. 10, 2021
Entity File Number 001-39746
Entity Registrant Name SIGILON THERAPEUTICS, INC.
Entity Incorporation, State or Country Code DE
Entity Tax Identification Number 47-4005543
Entity Address, Address Line One 100 Binney Street
Entity Address, Adress Line Two Suite 600
Entity Address, City or Town Cambridge
Entity Address, State or Province MA
Entity Address, Postal Zip Code 02142
City Area Code 617
Local Phone Number 336-7540
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Title of 12(b) Security Common Stock, $0.001 par value per share
Trading Symbol SGTX
Security Exchange Name NASDAQ
Entity Emerging Growth Company true
Entity Ex Transition Period false
Entity Central Index Key 0001821323
Amendment Flag false
EXCEL 9 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 10 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 11 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 12 FilingSummary.xml IDEA: XBRL DOCUMENT 3.21.2 html 1 96 1 false 0 0 false 0 false false R1.htm 00090 - Document - Document and Entity Information Sheet http://www.sigilon.com/role/DocumentDocumentAndEntityInformation Document and Entity Information Cover 1 false false All Reports Book All Reports sgtx-20211110x8k.htm sgtx-20211110.xsd sgtx-20211110_lab.xml sgtx-20211110_pre.xml sgtx-20211110xex99d1.htm http://xbrl.sec.gov/dei/2020-01-31 true false JSON 14 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "sgtx-20211110x8k.htm": { "axisCustom": 0, "axisStandard": 0, "contextCount": 1, "dts": { "inline": { "local": [ "sgtx-20211110x8k.htm" ] }, "labelLink": { "local": [ "sgtx-20211110_lab.xml" ] }, "presentationLink": { "local": [ "sgtx-20211110_pre.xml" ] }, "schema": { "local": [ "sgtx-20211110.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd", "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd", "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/deprecated-2009-12-16.xsd" ] } }, "elementCount": 25, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2020-01-31": 2, "total": 2 }, "keyCustom": 0, "keyStandard": 96, "memberCustom": 0, "memberStandard": 0, "nsprefix": "sgtx", "nsuri": "http://www.sigilon.com/20211110", "report": { "R1": { "firstAnchor": { "ancestors": [ "p", "div", "div", "body", "html" ], "baseRef": "sgtx-20211110x8k.htm", "contextRef": "Duration_11_10_2021_To_11_10_2021_ot7TxydcF0q000dB1LSN-g", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "00090 - Document - Document and Entity Information", "role": "http://www.sigilon.com/role/DocumentDocumentAndEntityInformation", "shortName": "Document and Entity Information", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "p", "div", "div", "body", "html" ], "baseRef": "sgtx-20211110x8k.htm", "contextRef": "Duration_11_10_2021_To_11_10_2021_ot7TxydcF0q000dB1LSN-g", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 0, "tag": { "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.sigilon.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.sigilon.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Document and Entity Information [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "xbrltype": "stringItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented. If there is no historical data in the report, use the filing date. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.sigilon.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "dateItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.sigilon.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "submissionTypeItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.sigilon.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine2": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 2 such as Street or Suite number", "label": "Entity Address, Adress Line Two" } } }, "localname": "EntityAddressAddressLine2", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.sigilon.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.sigilon.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.sigilon.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.sigilon.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.sigilon.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.sigilon.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntityExTransitionPeriod": { "auth_ref": [ "r7" ], "lang": { "en-us": { "role": { "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.", "label": "Entity Ex Transition Period" } } }, "localname": "EntityExTransitionPeriod", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.sigilon.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.sigilon.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "fileNumberItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.sigilon.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.sigilon.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.sigilon.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "employerIdItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.sigilon.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre-commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.sigilon.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r3" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre-commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.sigilon.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r0" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.sigilon.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.sigilon.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r4" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.sigilon.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.sigilon.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r6" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.sigilon.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" } }, "unitCount": 0 } }, "std_ref": { "r0": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b" }, "r1": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1" }, "r2": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c" }, "r3": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b" }, "r4": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12" }, "r5": { "Name": "Regulation 12B", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r6": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425" }, "r7": { "Name": "Securities Act", "Number": "7A", "Publisher": "SEC", "Section": "B", "Subsection": "2" } }, "version": "2.1" } ZIP 15 0001558370-21-015515-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001558370-21-015515-xbrl.zip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end